LIU Changxiao, male, academician of Chinese Academy of Engineering, researcher, professor, doctoral supervisor, graduated from the Pharmacy Department of Beijing Medical College (Peking University School of Pharmaceutical Sciences now) in 1965. He is a member of the National New Drug R&D Expert Committee, a member of the National Science and Technology Economic Expert Committee, a member of the National GLP Expert Committee, ajury of National New Drug, an executive director of the Chinese Pharmacological Society and the deputy director of its branch-the Drug Metabolism Committee, a member of the ProfessionalCommittee of Mathematical Pharmacology and Pharmaceutical Industry. What’s more, he is the Honorary Dean of School of Pharmacy of Henan University.

Academician LIU Changxiao has been engaged in pharmacokinetics study for 40 years and is one of the pioneers of pharmacokinetics in China. In 1968, he established the first pharmacokinetic laboratory in Chinaand published the first monograph on pharmacokinetics in China in 1980. In 1975 he was the first one to apply the subject to the evaluation and identification of new drugs. In the 1970s, he applied the discipline to the research of new drugs for the treatment of schistosomiasis, and proposed a low-dose and short-course treatment program, which produced significant social and economic benefits. In 2003, he founded Tianjin State Key Laboratory of Pharmacokinetics and Pharmacodynamics (breeding base). In the same year, he advocated metabolomics research in China, especially the metabolomics research of traditional Chinese medicine.

Since 1985, he has undertaken 25 National Programs for Science and Technology, New Drug Funds, 863 Program (National High Technology Research and Development Program of China) and other major research projects. The “Pre-clinical Pharmacokinetic Specification Research of Prodrugs and Biotechnology Drugs” has been listed as the top priority of National Science and Technology. As one of the researchers in the Practical Pharmacokinetic Calculation Program, he proposed model optimization, automatic calculation, and data batch processing. He also participated in the drafting of the National Drug Safety Evaluation Management Specification (GLP) and its implementation rules and acceptance guidelines. He is the first to report the whitening effect of berbamine. And he has published more than 210 papers at home and abroad and 12 monographs in both Chinese and English, receiving 27 provincial and international academic achievement awards from the Ministry of State. In 2000, he won the first Award of Chinese Hong Kong Redbud Medicine (Development and) Achievement/Hong Kong Bauhinia Medical Achievement Award and Medical Innovation Award. In 1992, he received a government allowance from the State Council and in 2003, he was elected academician of the Chinese Academy of Engineering.